Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2018

01-09-2018 | Epidemiology

The relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among elderly women with incident breast cancer

Published in: Breast Cancer Research and Treatment | Issue 2/2018

Login to get access

Abstract

Purpose

To examine the relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among a population-based cohort of elderly women with incident breast cancer, with a special focus on identifying sources of socioeconomic (SES) disparities in outcomes.

Methods

We identified women with newly diagnosed breast cancer in 2006–2009 from the Surveillance and Epidemiology End Result study linked with Medicare claims. A Classification and Regression Tree (CART) model was applied to 13 individual indicators of neoadjuvant and adjuvant breast cancer treatment, tumor characteristics, and patient sociodemographic variables to identify patterns with the greatest discriminant value in predicting 5-year survival. We subsequently examined the extent to which these patterns varied by the patient’s SES.

Results

Survival probabilities associated with the 18 unique CART-identified patterns ranged from 22 to 87%. The number of positive axillary nodes was the best single discriminator between high and lower survival outcomes. The most common discriminant factor among patterns with poor (< 25%) survival was the absence of radiation treatment, followed by the presence of comorbidities, tumor size > 2 cm, and no breast surgery. Relative to high SES women, poor women were nearly four times (12.3% vs. 3.2%, p < 0.001) as likely to be classified in the pattern associated with worse survival, and less likely (31.7% vs. 52.9%, p = 0.04) to receive the pattern associated with the greatest survival.

Conclusions

Greater adoption of effective patterns of care could improve survival of elderly women with incident breast cancer overall, and reduce SES disparities therein.
Appendix
Available only for authorised users
Literature
1.
go back to reference Singh GK, Miller B, Hankey B, Edwards BK (2003) Area socioeconomic variations in U.S. Cancer Incidence, Mortality, Stage, Treatment, and Survival, 1975–1999. In. National Cancer Institute, Bethesda Singh GK, Miller B, Hankey B, Edwards BK (2003) Area socioeconomic variations in U.S. Cancer Incidence, Mortality, Stage, Treatment, and Survival, 1975–1999. In. National Cancer Institute, Bethesda
2.
go back to reference Gordon NH, Crowe JP, Brumberg DJ, Berger NA (1992) Socioeconomic factors and race in breast cancer recurrence and survival. Am J Epidemiol 135(6):609–618CrossRefPubMed Gordon NH, Crowe JP, Brumberg DJ, Berger NA (1992) Socioeconomic factors and race in breast cancer recurrence and survival. Am J Epidemiol 135(6):609–618CrossRefPubMed
3.
go back to reference Gorey KM, Luginaah IN, Holowaty EJ, Fung KY, Hamm C (2009) Breast cancer survival in Ontario and California, 1998–2006: socioeconomic inequity remains much greater in the United States. Ann Epidemiol 19(2):121–124CrossRefPubMedPubMedCentral Gorey KM, Luginaah IN, Holowaty EJ, Fung KY, Hamm C (2009) Breast cancer survival in Ontario and California, 1998–2006: socioeconomic inequity remains much greater in the United States. Ann Epidemiol 19(2):121–124CrossRefPubMedPubMedCentral
4.
go back to reference Sprague BL, Trentham-Dietz A, Gangnon RE, Ramchandani R, Hampton JM, Robert SA, Remington PL, Newcomb PA (2011) Socioeconomic status and survival after an invasive breast cancer diagnosis. Cancer 117(7):1542–1551CrossRefPubMed Sprague BL, Trentham-Dietz A, Gangnon RE, Ramchandani R, Hampton JM, Robert SA, Remington PL, Newcomb PA (2011) Socioeconomic status and survival after an invasive breast cancer diagnosis. Cancer 117(7):1542–1551CrossRefPubMed
5.
go back to reference Harper S, Lynch J, Meersman SC, Breen N, Davis WW, Reichman MC (2009) Trends in area-socioeconomic and race-ethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987–2005). Cancer Epidemiol Biomark Prev 18(1):121–131CrossRef Harper S, Lynch J, Meersman SC, Breen N, Davis WW, Reichman MC (2009) Trends in area-socioeconomic and race-ethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987–2005). Cancer Epidemiol Biomark Prev 18(1):121–131CrossRef
6.
go back to reference Byers TE, Wolf HJ, Bauer KR, Bolick-Aldrich S, Chen VW, Finch JL, Fulton JP, Schymura MJ, Shen T, Van Heest S et al (2008) The impact of socioeconomic status on survival after cancer in the United States: findings from the National Program of Cancer Registries Patterns of Care Study. Cancer 113(3):582–591CrossRefPubMed Byers TE, Wolf HJ, Bauer KR, Bolick-Aldrich S, Chen VW, Finch JL, Fulton JP, Schymura MJ, Shen T, Van Heest S et al (2008) The impact of socioeconomic status on survival after cancer in the United States: findings from the National Program of Cancer Registries Patterns of Care Study. Cancer 113(3):582–591CrossRefPubMed
8.
go back to reference Kish JK, Yu M, Percy-Laurry A, Altekruse SF (2014) Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in Surveillance, Epidemiology, and End Results (SEER) Registries. J Natl Cancer Inst Monogr 2014(49):236–243CrossRefPubMedPubMedCentral Kish JK, Yu M, Percy-Laurry A, Altekruse SF (2014) Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in Surveillance, Epidemiology, and End Results (SEER) Registries. J Natl Cancer Inst Monogr 2014(49):236–243CrossRefPubMedPubMedCentral
9.
go back to reference Feinglass J, Rydzewski N, Yang A (2015) The socioeconomic gradient in all-cause mortality for women with breast cancer: findings from the 1998 to 2006 National Cancer Data Base with follow-up through 2011. Ann Epidemiol 25(8):549–555CrossRefPubMed Feinglass J, Rydzewski N, Yang A (2015) The socioeconomic gradient in all-cause mortality for women with breast cancer: findings from the 1998 to 2006 National Cancer Data Base with follow-up through 2011. Ann Epidemiol 25(8):549–555CrossRefPubMed
10.
go back to reference Gilligan MA, Kneusel RT, Hoffmann RG, Greer AL, Nattinger AB (2002) Persistent differences in sociodemographic determinants of breast conserving treatment despite overall increased adoption. Med Care 40(3):181–189CrossRefPubMed Gilligan MA, Kneusel RT, Hoffmann RG, Greer AL, Nattinger AB (2002) Persistent differences in sociodemographic determinants of breast conserving treatment despite overall increased adoption. Med Care 40(3):181–189CrossRefPubMed
11.
go back to reference Nattinger AB, Wozniak EM, McGinley EL, Li J, Laud P, Pezzin LE (2017) Socioeconomic disparities in mortality among women with incident breast cancer before and after implementation of medicare Part D. Med Care 55(5):463–469CrossRefPubMed Nattinger AB, Wozniak EM, McGinley EL, Li J, Laud P, Pezzin LE (2017) Socioeconomic disparities in mortality among women with incident breast cancer before and after implementation of medicare Part D. Med Care 55(5):463–469CrossRefPubMed
13.
go back to reference Reeder-Hayes K, Peacock Hinton S, Meng K, Carey LA, Dusetzina SB (2016) Disparities in use of human epidermal growth hormone receptor 2-targeted therapy for early-stage breast cancer. J Clin Oncol 34(17):2003–2009CrossRefPubMedPubMedCentral Reeder-Hayes K, Peacock Hinton S, Meng K, Carey LA, Dusetzina SB (2016) Disparities in use of human epidermal growth hormone receptor 2-targeted therapy for early-stage breast cancer. J Clin Oncol 34(17):2003–2009CrossRefPubMedPubMedCentral
14.
go back to reference Lautner M, Lin H, Shen Y, Parker C, Kuerer H, Shaitelman S, Babiera G, Bedrosian I (2015) Disparities in the use of breast-conserving therapy among patients with early-stage breast cancer. JAMA Surg 150(8):778–786CrossRefPubMedPubMedCentral Lautner M, Lin H, Shen Y, Parker C, Kuerer H, Shaitelman S, Babiera G, Bedrosian I (2015) Disparities in the use of breast-conserving therapy among patients with early-stage breast cancer. JAMA Surg 150(8):778–786CrossRefPubMedPubMedCentral
15.
go back to reference Royak-Schaler R, Pelser C, Langenberg P, Hayes J, Gardner L, Nesbitt K, Citron W, Drogula CL, Dwyer D (2012) Characteristics associated with the initiation of radiation therapy after breast-conserving surgery among African American and white women diagnosed with early-stage breast cancer in Maryland, 2000–2006. Ann Epidemiol 22(1):28–36CrossRefPubMed Royak-Schaler R, Pelser C, Langenberg P, Hayes J, Gardner L, Nesbitt K, Citron W, Drogula CL, Dwyer D (2012) Characteristics associated with the initiation of radiation therapy after breast-conserving surgery among African American and white women diagnosed with early-stage breast cancer in Maryland, 2000–2006. Ann Epidemiol 22(1):28–36CrossRefPubMed
16.
go back to reference Parise CA, Bauer KR, Caggiano V (2012) Disparities in receipt of adjuvant radiation therapy after breast-conserving surgery among the cancer-reporting regions of California. Cancer 118(9):2516–2524CrossRefPubMed Parise CA, Bauer KR, Caggiano V (2012) Disparities in receipt of adjuvant radiation therapy after breast-conserving surgery among the cancer-reporting regions of California. Cancer 118(9):2516–2524CrossRefPubMed
17.
go back to reference Chen AY, Halpern MT, Schrag NM, Stewart A, Leitch M, Ward E (2008) Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998–2005). J Natl Cancer Inst 100(7):462–474CrossRefPubMed Chen AY, Halpern MT, Schrag NM, Stewart A, Leitch M, Ward E (2008) Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998–2005). J Natl Cancer Inst 100(7):462–474CrossRefPubMed
18.
go back to reference Reeder-Hayes KE, Bainbridge J, Meyer AM, Amos KD, Weiner BJ, Godley PA, Carpenter WR (2011) Race and age disparities in receipt of sentinel lymph node biopsy for early-stage breast cancer. Breast Cancer Res Treat 128(3):863–871CrossRefPubMedPubMedCentral Reeder-Hayes KE, Bainbridge J, Meyer AM, Amos KD, Weiner BJ, Godley PA, Carpenter WR (2011) Race and age disparities in receipt of sentinel lymph node biopsy for early-stage breast cancer. Breast Cancer Res Treat 128(3):863–871CrossRefPubMedPubMedCentral
20.
go back to reference Breiman L, Friedman JH, Olshen RA, Stone CJ (1984) Classification and regression trees. Wadsworth & Brooks/Cole Advanced Books & Software, Monterey Breiman L, Friedman JH, Olshen RA, Stone CJ (1984) Classification and regression trees. Wadsworth & Brooks/Cole Advanced Books & Software, Monterey
21.
go back to reference Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53(12):1258–1267CrossRefPubMed Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53(12):1258–1267CrossRefPubMed
22.
go back to reference Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH (2016) Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol 2(3):322–329CrossRefPubMedPubMedCentral Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH (2016) Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol 2(3):322–329CrossRefPubMedPubMedCentral
23.
go back to reference Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI (2006) Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys 65(5):1353–1360CrossRefPubMed Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI (2006) Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys 65(5):1353–1360CrossRefPubMed
24.
go back to reference Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI (2006) Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat 99(3):313–321CrossRefPubMed Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI (2006) Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat 99(3):313–321CrossRefPubMed
25.
go back to reference Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MM (2015) Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients. BMJ 351:h4901CrossRefPubMedPubMedCentral Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MM (2015) Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients. BMJ 351:h4901CrossRefPubMedPubMedCentral
26.
go back to reference Michaelson JS, Silverstein M, Sgroi D, Cheongsiatmoy JA, Taghian A, Powell S, Hughes K, Comegno A, Tanabe KK, Smith B (2003) The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer 98(10):2133–2143CrossRefPubMed Michaelson JS, Silverstein M, Sgroi D, Cheongsiatmoy JA, Taghian A, Powell S, Hughes K, Comegno A, Tanabe KK, Smith B (2003) The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer 98(10):2133–2143CrossRefPubMed
27.
go back to reference Say CC, Donegan WL (1974) Invasive carcinoma of the breast: prognostic significance of tumor size and involved axillary lymph nodes. Cancer 34(2):468–471CrossRefPubMed Say CC, Donegan WL (1974) Invasive carcinoma of the breast: prognostic significance of tumor size and involved axillary lymph nodes. Cancer 34(2):468–471CrossRefPubMed
28.
go back to reference Braithwaite D, Moore DH, Satariano WA, Kwan ML, Hiatt RA, Kroenke C, Caan BJ (2012) Prognostic impact of comorbidity among long-term breast cancer survivors: results from the LACE study. Cancer Epidemiol Biomarkers Prev 21(7):1115–1125CrossRefPubMedPubMedCentral Braithwaite D, Moore DH, Satariano WA, Kwan ML, Hiatt RA, Kroenke C, Caan BJ (2012) Prognostic impact of comorbidity among long-term breast cancer survivors: results from the LACE study. Cancer Epidemiol Biomarkers Prev 21(7):1115–1125CrossRefPubMedPubMedCentral
29.
go back to reference Zhao XB, Ren GS (2016) Diabetes mellitus and prognosis in women with breast cancer: A systematic review and meta-analysis. Medicine (Baltimore) 95(49):e5602CrossRef Zhao XB, Ren GS (2016) Diabetes mellitus and prognosis in women with breast cancer: A systematic review and meta-analysis. Medicine (Baltimore) 95(49):e5602CrossRef
30.
go back to reference Chen L, Linden HM, Anderson BO, Li CI (2014) Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage. Breast Cancer Res Treat 147(3):609–616CrossRefPubMedPubMedCentral Chen L, Linden HM, Anderson BO, Li CI (2014) Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage. Breast Cancer Res Treat 147(3):609–616CrossRefPubMedPubMedCentral
31.
go back to reference Early Breast Cancer Trialists’ Collaborative G, Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444CrossRef Early Breast Cancer Trialists’ Collaborative G, Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444CrossRef
32.
go back to reference Early Breast Cancer Trialists’ Collaborative G (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001):1341–1352CrossRef Early Breast Cancer Trialists’ Collaborative G (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001):1341–1352CrossRef
33.
go back to reference Early Breast Cancer Trialists’ Collaborative G, Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784CrossRef Early Breast Cancer Trialists’ Collaborative G, Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784CrossRef
34.
go back to reference Early Breast Cancer Trialists' Collaborative G, Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M (2011) M et al: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716CrossRef Early Breast Cancer Trialists' Collaborative G, Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M (2011) M et al: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716CrossRef
35.
go back to reference Ebctcg McGaleP, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127–2135CrossRef Ebctcg McGaleP, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127–2135CrossRef
36.
go back to reference Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP et al (2013) Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 31(19):2382–2387CrossRefPubMedPubMedCentral Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP et al (2013) Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 31(19):2382–2387CrossRefPubMedPubMedCentral
37.
go back to reference Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, Investigators AL (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12):1135–1141CrossRefPubMed Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, Investigators AL (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12):1135–1141CrossRefPubMed
38.
go back to reference Wang Y, Witten I (1997) Inducing model trees for continuous classes. In: Proceedings of the ninth european conference machine learning Wang Y, Witten I (1997) Inducing model trees for continuous classes. In: Proceedings of the ninth european conference machine learning
39.
go back to reference Gornick M (2000) Vulnerable populations and medicare services: why do disparities exist? Century Foundation Press, New York, NY Gornick M (2000) Vulnerable populations and medicare services: why do disparities exist? Century Foundation Press, New York, NY
40.
go back to reference Du XL, Fang S, Meyer TE (2008) Impact of treatment and socioeconomic status on racial disparities in survival among older women with breast cancer. Am J Clin Oncol 31(2):125–132CrossRefPubMed Du XL, Fang S, Meyer TE (2008) Impact of treatment and socioeconomic status on racial disparities in survival among older women with breast cancer. Am J Clin Oncol 31(2):125–132CrossRefPubMed
41.
go back to reference Nattinger AB, Pezzin LE, McGinley EL, Charlson JA, Yen TW, Neuner JM (2015) Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations. Springerplus 4:54CrossRefPubMedPubMedCentral Nattinger AB, Pezzin LE, McGinley EL, Charlson JA, Yen TW, Neuner JM (2015) Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations. Springerplus 4:54CrossRefPubMedPubMedCentral
42.
go back to reference Dreyer MS, Nattinger AB, McGinley EL, Pezzin LE (2018) Socioeconomic status and breast cancer treatment. Breast Cancer Res Treat 167(1):1–8CrossRefPubMed Dreyer MS, Nattinger AB, McGinley EL, Pezzin LE (2018) Socioeconomic status and breast cancer treatment. Breast Cancer Res Treat 167(1):1–8CrossRefPubMed
Metadata
Title
The relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among elderly women with incident breast cancer
Publication date
01-09-2018
Published in
Breast Cancer Research and Treatment / Issue 2/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4837-4

Other articles of this Issue 2/2018

Breast Cancer Research and Treatment 2/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine